A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C.

Chi-Yi ChenWan-Long ChuangAlbert QinWen-Hua ZhangLi-Ying ZhuGuo-Qiang ZhangJyh-Jou ChenChing-Chu LoXinmin ZhouXiaorong MaoJia ShangHsing-Tao KuoWen XieChien-Hung ChenGin-Ho LoDae Won JunShuangsuo DangChan-Yen TsaiTing-Fang WangHsin-Hui LaiKuan-Chiao TsengYi-Wen HuangPei-Jer Chen

Published in: JGH open : an open access journal of gastroenterology and hepatology (2022)

Ropeginterferon alfa-2b is efficacious and has a favorable safety profile as compared with the conventional pegylated interferon alfa-2b. This study together with previous Phase 2 data validated ropeginterferon alfa-2b to be a new treatment option for chronic hepatitis C genotype 2.

Keyphrases

replacement therapy
clinical trial
dendritic cells
liver fibrosis
electronic health record
big data
randomized controlled trial
combination therapy
study protocol
immune response
machine learning
phase iii
recombinant human